## **Oncology Clinical Pathways Breast Cancer Risk Reduction**

August 2024 - V1.2024







## **Table of Contents**


Breast Cancer Risk Reduction	
Pathogenic/Likely Pathogenic Germline Genetic Variant for an Increased Risk of Breast Cancer	







## **Breast Cancer Risk Reduction**



<sup>a</sup> High Risk Patients screening for high risk patients includes annual mammogram and annual MRI for patients with ≥20% lifetime risk based on risk models such as Tyrer-Cuzick; common practice is alternating mammogram and MRI every 6 months; if assistance is needed, refer to a local high risk breast clinic or the National TeleOncology high risk breast clinic for discussion of risk-reducing strategy

Prisk Factors include Gail Model ≥ 1.7% at 5 years, Tyrer-Cuzick > 5% at 10 years, received chest irradiation prior to age 30, ADH/ALH, LCIS, or pathogenic/likely pathogenic germline genetic variant

Tamoxifen Contraindications history of DVT, PE, or stroke; known hypersensitivity to tamoxifen, pregnancy, uterine malignancy, concomitant warfarin therapy

Tamoxifen if providing 10mg, take one tablet every other day

ADH/ALH Atypical Ductal Hyperplasia/Atypical Lobular Hyperplasia LCIS Lobular carcinoma in situ RRA Risk Reducing Agent







## Pathogenic/Likely Pathogenic Germline Genetic Variant for an Increased Risk of Breast Cancer

Pathogenic/Likely Pathogenic Germline Genetic Variant for an Increased Risk of Breast Cancer ab		
ATM	<ul> <li>Screening: annual mammogram starting at age 40 years and consider breast MRI starting at age 3035 years</li> <li>RRM: evidence insufficient; manage based on family history</li> </ul>	
BARD1	<ul> <li>Screening: annual mammogram and consider breast MRI starting at age 40 years</li> <li>RRM: evidence insufficient; manage based on family history</li> </ul>	
BRCA1 Male Birth Sex	Self-exam training and clinical breast exam q12m starting at age 35 years	
BRCA1 Female Birth Sex	<ul> <li>Screening: annual breast MRI starting at age 25 years; mammogram and breast MRI age 30-75 years; &gt;75 years manage based on individual basis</li> <li>RRM: discuss option of RRM</li> </ul>	
BRCA2 Male Birth Sex	Self-exam training and clinical breast exam q12m starting at age 35 years; consider annual mammogram starting at age 50 years or 10 years before the earliest known male breast cancer in the family	
BRCA2 Female Birth Sex	<ul> <li>Screening: annual breast MRI starting at age 25 years; mammogram and breast MRI age 30-75 years; &gt;75 years manage based on individual basis</li> <li>RRM: discuss option of RRM</li> </ul>	
CDH1	<ul> <li>Screening: annual mammogram and breast MRI starting at age 30</li> <li>RRM: discuss option of RRM</li> </ul>	
CHEK2	<ul> <li>Screening: consider breast MRI starting at age 30-35 years; annual mammogram starting at age 40 years</li> <li>RRM: evidence insufficient; manage based on family history</li> </ul>	
NF1	<ul> <li>Screening: annual mammogram starting at age 30 years and breast MRI starting from ages 30-50 years</li> <li>RRM: evidence insufficient; manage based on family history</li> </ul>	
PALB2 Male Birth Sex	Self-exam training and clinical breast exam q12m starting at age 35 years	
PALB2 Female Birth Sex	<ul> <li>Screening: annual mammogram starting and breast MRI at age 30 years</li> <li>RRM: discuss option of RRM</li> </ul>	
PTEN	<ul> <li>Screening: annual mammogram and breast MRI starting at age 30 years or 10 years before the earliest known breast cancer in the family up to 75 years of age; &gt;75 years manage based on individual basis</li> <li>RRM: discuss option of RRM</li> </ul>	
RAD51C, RAD51D	<ul> <li>Screening: annual mammogram and breast MRI starting at age 40 years</li> <li>RRM: evidence insufficient; manage based on family history</li> </ul>	
STK11	<ul> <li>Screening: annual mammogram and breast MRI starting at age 30 years</li> <li>RRM: discuss option of RRM</li> </ul>	
TP53	<ul> <li>Screening: annual breast MRI age 20-29 years, mammogram and breast MRI age 30-75 years, &gt;75 years manage based on individual basis</li> <li>RRM: discuss option of RRM</li> </ul>	
BRIP1, CDKN2A, EPCAM, MSH2, MLH1, MSH6, PMS2	Screening and RRM: evidence insufficient; manage based on family history	

<sup>&</sup>lt;sup>a</sup> High Risk Patients screening includes annual mammogram and annual MRI for patients with ≥20% lifetime risk based on risk models such as Tyrer-Cuzick; common practice is alternating mammogram and MRI every 6 months

**RRM** Risk-Reducing Mastectomy







<sup>&</sup>lt;sup>b</sup> Germline Genetic Considerations pathogenic/likely pathogenic germline findings may also increase risk for other cancers; consider options to address other risk management such as genetics annual follow-up clinic